AXSOME
PharmaAXSOME is a pharmaceutical company focused on Neurology. Key products include AUVELITY.
AXSOME at a Glance
- Fast trial execution (16 months median completion)
AXSOME's Key Drugs
AXSOME's core commercial portfolio centers on AUVELITY, SYMBRAVO, spanning Neurology — its most strategically important drugs approved in the last 15 years.
AXSOME's Recent FDA Approvals
AXSOME secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
AXSOME's Therapeutic Areas
AXSOME's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AXSOME's Top Competitors
AXSOME's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AXSOME Pipeline Snapshot
AXSOME has 9 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 1 Phase 2 and 0 Phase 1.
Phase 3 Readout Calendar Pro
4 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 14/20 completed
- • Speed: 16 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges